College football hasn’t been ruined. It’s been exposed.
The transfer portal and NIL money didn’t break the sport. They simply ended a long-standing, unspoken agreement that favored institutions far more than the individuals inside them. What we’re watching now is a market correction. It’s messy, public, and uncomfortable and it looks remarkably familiar to anyone who has hired senior talent in life sciences over the last decade.
The same forces reshaping college athletics are reshaping executive hiring in biotech, pharma, and medtech. Once you see the parallels, it’s hard to unsee them.
When Power Shifts to the Individual
For years, college programs controlled the terms. Coaches could leave when opportunity called. Players could not. Loyalty was expected from one side and optional from the other.
The transfer portal changed that overnight. Athletes can now assess their options, test the market, and move when the opportunity makes sense. They behave like free agents because, functionally, that’s what they are.
Life sciences went through a similar shift, particularly after COVID. Senior leaders began to realize that loyalty wasn’t a guarantee of stability and that leverage was real. Optionality mattered. Career decisions became more intentional.
Executives who once stayed put for predictability now move when the scope, platform, or upside is clearly stronger elsewhere. Not because they’re disloyal, but because the market allows them to be selective.
Transparency Changed the Conversation Around Value
NIL deals stripped away the polite fiction that college football was only “about the education.” Money had always been part of the equation. It just wasn’t visible.
Once compensation became public, every deal became a reference point. Expectations shifted, and they didn’t shift back.
Life sciences experienced the same reset. Compensation surveys, equity disclosures, public filings, and more states implementing pay transparency laws eliminated the ability to hide behind vague statements like “we pay competitively.”
Senior candidates now know what peers are earning, how equity differs by stage, and what upside looks like in different scenarios. Conversations are more direct. Negotiations move faster. And once that level of transparency exists, there’s no returning to the old opacity.
Platform Matters as Much as Development
Top college programs no longer recruit solely on coaching and development. They sell exposure, sponsorship pipelines, personal brand growth, and future opportunity.
Life sciences executives evaluate roles through a similar lens. They want to understand whether a platform elevates their profile, whether the company carries credibility with investors and partners, and whether the role meaningfully compounds their future value.
Development still matters. But trajectory matters more. Senior leaders are thinking two or three moves ahead, not just about the next title or compensation band.
Retention Became the Harder Problem
Many college programs didn’t lose players because they were failing. They lost them because someone else presented a stronger near-term opportunity.
That reality is deeply familiar to life sciences leadership teams.
The most competitive searches today aren’t for unemployed talent. They’re for capable, reasonably content executives who weren’t planning to move until someone reframed the opportunity in a way that made staying feel riskier than leaving.
Retention now requires just as much intention as recruiting. Assuming people will stay because they always have is no longer a strategy.
What This Looks Like in Life Sciences Hiring
The parallels are clear.
The transfer portal mirrors the passive candidate market. Talent is always available, but only to organizations that recruit continuously rather than reactively.
NIL deals resemble modern total rewards packages. Cash matters, but so does equity, scope, visibility, governance access, autonomy, and future upside. Money opens the door. Everything else determines whether someone walks through it.
Blue-chip college programs look a lot like legacy life sciences brands. They still win often, but reputation alone no longer carries the day.
And the programs punching above their weight look like smart growth-stage biotechs. With a clear mission, credible leadership, and a well-defined role, they can out-recruit competitors with deeper pockets.
The Hard Truth for CEOs and Boards
The old talent model was built on loyalty, patience, limited information, and restricted mobility.
The current market rewards clarity, speed, credibility, and an honest understanding of how talent actually moves.
Organizations that spend time lamenting how hiring “used to work” are already falling behind. The shift didn’t happen overnight, but the consequences are now impossible to ignore.
Senior candidates expect straightforward conversations about risk and reward, clarity on why a role matters now, and confidence that leadership understands the market they’re operating in. That isn’t entitlement. It’s the reality of a more informed talent economy.
Where Many Leaders Still Miss the Mark
Too many life sciences companies are still hiring as if it’s 2005. They lean too heavily on loyalty, delay decisions, under-explain risk, and assume brand alone will do the heavy lifting.
Meanwhile, competitors move faster, communicate more openly, and treat senior talent like the strategic asset it is.
The outcome is predictable. The best players take the field somewhere else.
Hiring for the Market We’re Actually In
College football didn’t become broken. It became honest.
The same thing is happening in life sciences hiring. The companies that adapt will build leadership teams that last. The ones that cling to old rules will keep blaming the market while watching talent walk out the door.
At GeneCoda®, we work with life sciences leaders who understand that executive hiring today isn’t about filling seats. It’s about competing in a transparent, fast-moving talent market where clarity, credibility, and timing matter. If you want to build leadership teams that thrive under today’s rules, we can help. Contact GeneCoda® to discuss how your executive hiring strategy needs to evolve for the market you’re actually in.
